Modernizing Medicine Closes First $15M Tranche of Expected $20M Round of Funding

 

BOCA RATON, Fla.--Modernizing Medicine, Inc., the creator of the Electronic Medical Assistant®(EMA™), a cloud-based, specialty-specific electronic medical record (EMR) system, announced that it has closed on approximately $15M of an expected $20M funding round. The latest funding comes from existing investors, led by Summit Partners and Pentland Group, many of whom are medical specialists who use EMA.

Developed by surgical physicians, EMA contains built-in specialty-specific medical knowledge and workflows. It can be accessed via the Internet virtually anywhere and at any time. This flexible format, combined with EMA’s touch-screen interface and advanced ICD-10 capabilities, gives providers the freedom they need to focus on their patients with the reassurance that charting plus coding for billing can be completed at the point of care.“At Modernizing Medicine we believe that properly captured and leveraged health data has the power to increase efficiency, improve patient outcomes and transform healthcare,” said Daniel Cane, CEO and co-founder of Modernizing Medicine. “This latest round of funding reinforces that belief and the strength of our market-differentiating products and services. With the investment we intend to continue focused development in the surgical-specialties, while also committing resources for development in telemedicine, IBM Watson and mobile applications.”

Currently serving eight different medical specialties, more than 4,000 providers have adopted Modernizing Medicine’s EMA in their practices.

“Healthcare professionals need tailored technologies that make it easy not only to manage but also benefit from the exploding amounts of patient data,” said Michael Sherling, MD, Modernizing Medicine’s co-founder and chief medical officer. “In a relatively short time, we have developed a solution that does just that, enabling us to capture substantial market share and emerge as a physician-favorite EMR system. In the dermatology specialty alone, more than 26 percent of U.S. dermatologists now use EMA.”

Modernizing Medicine continues to be recognized for its exceptional culture, leadership and growth. The company expects its employee base to continue to grow with approximately 100 new positions being created in the next 12-18 months. Co-founders Cane and Sherling were recently honored with the Leadership in Health Care Award by the U.S. Chamber of Commerce. The company was also named in Red Herring’s Top 100 North America list, which recognizes the top private companies across the continent that are expected to achieve significant growth in the near future.

About Modernizing Medicine

Modernizing Medicine® is transforming how healthcare information is created, consumed and utilized in order to increase efficiency and improve outcomes. Our product, Electronic Medical Assistant® (EMA™), is a cloud-based, specialty-specific electronic medical record (EMR) system with a massive library of built-in medical content. Available as a native iPad application or from almost any web-enabled Mac or PC, EMA adapts to each provider’s unique style of practice and is designed to interface with hundreds of different practice management systems. Today, Modernizing Medicine provides specialty-specific offerings for the dermatology, ophthalmology, orthopedics, otolaryngology, gastroenterology, rheumatology, urology and plastic and cosmetic surgery markets and to more than 1,400 physician practices across the country.

Around the web

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.